wherein A is



R^3, R^4, R^5 and R^6 are each, independently, H, halogen, NO_2,

C_{1-10}- alkyl, optionally substituted by halogen up to perhaloalkyl,

C_{1-10}-alkoxy, optionally substituted by halogen up to perhaloalkoxy,

C_{1-10}- alkanoyl, optionally substituted by halogen up to perhaloalkanoyl,

C_{6-12} aryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy, or

C_{5-12} hetaryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy,

and either

one of R^3, R^4, R^5 and R^6 is –M-L^1; or

two adjacent of R^3, R^4, R^5 and R^6 together are an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10}-alkyl, , halo-substituted C_{1-10}-alkyl up to perhaloalkyl, C_{1-10}-alkoxy, halo-substituted C_{1-10}-alkoxy up to perhaloalkoxy, C_{3-10}-cycloalkyl, C_{2-10}-alkenyl, C_{1-10}-alkanoyl, C_{6-12}-aryl, C_{5-12}-hetaryl; C_{6-12}-aralkyl, C_{6-12}-alkaryl, halogen; NR^1R^1; $-NO_2$; $-CF_3$; -$COOR^1$; -$NHCOR^1$; -CN; -$CONR^1R^1$; -SO_2R^2; -SOR^2; -SR^2;

in which

R^1 is H or C_{1-10}-alkyl, optionally substituted by halogen up to perhaloalkyl and R^2 is C_{1-10}-alkyl, optionally substituted by halogen, up to perhaloalkyl,

$R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$ are independently H, halogen,

C_1 - C_{10} alkyl, optionally substituted by halogen up to perhaloalkyl,

C_1 –C_{10} alkoxy optionally substituted by halogen up to perhaloalkoxy or two adjacent of $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$, together with the base phenyl, form a naphthyl group, optionally substituted by halogen up to perhalo, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkanoyl, C_{6-12} aryl, C_{5-12} hetaryl or C_{6-12} aralkyl;

M is $-CH_2-$, -S-, $-N(CH_3)-$, -NHC(O)- $-CH_2-S-$, $-S-CH_2-$, -C(O)-, or –O-; and

L^1 is phenyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$, NO_2 or,



pyridyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$, or NO_2,

naphthyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyridone, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrazine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrimidine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzodioxane, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzopyridine, optionally substituted by C_{1-10}-alkyl, one C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

or

benzothiazole, optionally substituted by, C_{1-10} alkyl C_{1-10} alkoxy, halogen, OH, $-SCH_3$ or NO_2

or a pharmaceutically acceptable salt thereof.

3. (Amended) A compound according to claim 1, wherein

R^3 is H, halogen or C_{1-10}- alkyl, optionally substituted by halogen, up to perhaloalkyl;

R^4 is H, halogen or NO_2;

R^5 is H, halogen or C_{1-10}- alkyl;

R^6 is H, C_{1-10}- alkoxy, thiophene, pyrole or methyl substituted pyrole,

$R^{3'}$ is H, halogen, C_{4-10}-alkyl, or CF_3 and

$R^{6'}$ is H, halogen, CH_3, CF_3 or $-OCH_3$.

4. (Amended) A compound according to claim 1, wherein

$R^{3'}$ is C_{4-10}-alkyl, Cl, F or CF_3;

$R^{4'}$ is H, Cl or F ;

$R^{5'}$ is H, Cl, F or C_{4-10}-alkyl; and

$R^{6'}$ is H or OCH_3.

5. (Amended) A compound according to claim 4, wherein $R^{3'}$ or $R^{5'}$ is t-butyl.

6. (Amended) A compound according to claim 1, wherein M is $-CH_2-$, $-N(CH_3)-$ or $-NHC(O)-$.

7. (Amended) A compound according to claim 6, wherein L^1 is phenyl or pyridyl.

8. (Amended) A compound according to claim 1, wherein M is –O-.

9. (Amended) A compound according to claim 8, wherein L^1 is phenyl, pyridyl pyridone or benzothiazole.

10. (Amended) A compound according to claim 1, wherein M is –S-.

11. (Amended) A compound according to claim 10, wherein L^1 is phenyl or pyridyl.

15. (Amended) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of formula II:



II

or a pharmaceutically acceptable salt thereof wherein

A is



B is a substituted or unsubstituted, up to bicyclic aryl or heteroaryl moiety of up to 12 carbon atoms with at least one 6-member aromatic structure containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein if B is substituted it is substituted by one or more substituents selected from the group consisting of halogen, up to per-halo, and W_n, wherein n is 0-3 and each W is independently selected from the group consisting of –CN, -CO_2R^7, -$C(O)NR^7R^7$,
-$C(O)$-R^7, -NO_2, -OR^7, - SR^7, - NR^7R^7, -$NR^7C(O)OR^7$, -$NR^7C(O)R^7$, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl,C_1-C_{10} alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, optionally substituted with halogen, C_1-C_{10} alkyl, or C_1-C_{10} alkoxy; C_7-C_{24} alkaryl, optionally substituted with halogen, C_1-C_{10} alkyl, or C_1-C_{10} alkoxy; C_3-C_{13} heteroaryl, optionally substituted with halogen, C_1-C_{10} alkyl, or C_1-C_{10} alkoxy; C_4-C_{23} alkheteroaryl, optionally substituted with halogen, C_1-

C_{10} alkyl, or C_1-C_{10} alkoxy; substituted C_1-C_{10} alkyl, substituted C_2-C_{10} alkenyl, substituted C_2-C_{10} alkenoyl, substituted C_1-C_{10} alkoxy, substituted C_3-C_{10} cycloalkyl, substituted C_4-C_{23} alkheteroaryl and $-M-L^1$;

wherein if W is a substituted group which does not contain aryl or hetaryl moieties, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, NO_2, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ and halogen up to per-halo;

wherein each R^7 is independently selected from H, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} hetaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halo substituted C_2-C_{10} alkenyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} hetaryl,

wherein Q M is - O-, -S-, $-N(R^7)-$, $-(CH_2)_m-$, -C(O)-, -CH(OH)-, $-(CH_2)_mO-$, $-NR^7C(O)\ NR^7R^7-$, $-NR^7C(O)-$, $-C(O)NR^7-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^7)-$, $-O(CH_2)_m-$, $-CHX^a$, $-CX^a_2-$, $-S-(CH_2)_m-$ and $-N(R^7)(CH_2)_m-$,

m = 1-3, and X^a is halogen; and

L^1 is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur, which is unsubstituted or substituted by halogen up to per-halo and optionally substituted by Z_{n1}, wherein $_{n1}$ is 0 to 3 and each Z is independently selected from the group consisting of –CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-\ NR^7$, $-NO_2$, $-OR^7$, $-\ SR^7$, $-\ NR^7R^7$, $-NR^7C(O)OR^7$, $-C(O)R^7$, $-NR^7C(O)R^7$, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} hetaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein the one or more substituents of Z is selected from the group consisting of –CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NO_2$, $-NR^7R^7$, $-NR^7C(O)R^7$ and $-NR^7C(O)OR^7$,

wherein $R^{3'}$, $R^{4'}$,$R^{5'}$and $R^{6'}$ are each independently H, halogen, C_{1-10}-alkyl, optionally substituted by halogen up to perhaloalkyl,

87

C_1 –C_{10} alkoxy, optionally substituted by halogen up to perhaloalkoxy or two adjacent of $R^{3'}$,$R^{4'}$, $R^{5'}$ and $R^{6'}$ together with the base phenyl, form a naphthyl group, optionally substituted by halogen up to perhalo, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkanoyl, C_{6-12} aryl, C_{5-12} hetaryl or C_{6-12} aralkyl.

16. (Amended) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of formula IIa:



IIa

wherein A is



R^3, R^4, R^5 and R^6 are each independently H, halogen, NO_2,

C_{1-10}- alkyl, optionally substituted by halogen up to perhaloalkyl,

C_{1-10}-alkoxy, optionally substituted by halogen up to perhaloalkoxy,

C_{1-10}- alkanoyl, optionally substituted by halogen up to perhaloalkanoyl,

C_{6-12} aryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy, or

C_{5-12} hetaryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy,

and either

one of R^3, R^4, R^5 and R^6 is $-M-L^1$; or

two adjacent of R^3, R^4, R^5 and R^6 together are an aryl or hetaryl ring with 5- 12 atoms, optionally substituted by C_{1-10}-alkyl, halo-substituted C_{1-10}-alkyl up to perhaloalkyl, C_{1-10}-alkoxy, halo-substituted C_{1-10}-alkoxy up to perhaloalkoxy, C_{3-10}-cycloalkyl, C_{2-10}-alkenyl, C_{1-10}-alkanoyl; C_{6-12}-aryl, C_{5-12}-hetaryl, C_{6-12}-alkaryl, halogen; $-NR^1R^1$; $-NO_2$; $-CF_3$;$-COOR^1$; $-NHCOR^1$; -CN; $-CONR^1R^1$; $-SO_2R^2$; $-SOR^2$; $-SR^2$;

in which

R^1 is H or C_{1-10}-alkyl, optionally substituted by halogen, up to perhalo and

R^2 is C_{1-10}-alkyl, optionally substituted by halogen,

$R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$ are independently H, halogen,

C_1 - C_{10} alkyl, optionally substituted by halogen up to perhaloalkyl,

C_1 –C_{10} alkoxy optionally substituted by halogen up to perhaloalkoxy or

two adjacent of $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$, together with the base phenyl, form a naphthyl group optionally substituted by halogen up to perhalo, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkanoyl, C_{6-12} aryl, C_{5-12} hetaryl or C_{6-12} aralkyl, halogen up to perhalo ;

M is $-CH_2-$, -S-, $-N(CH_3)-$, -NHC(O)- $-CH_2-S-$, $-S-CH_2-$, -C(O)-, or –O-; and

L^1 is phenyl, pyridyl, naphthyl, pyridone, pyrazine, pyrimidine, benzodiaxane, benzopyridine or benzothiazole, each optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$, NO_2 or, where Y is phenyl, by



or a pharmaceutically acceptable salt thereof.

17. (Amended) A method according to claim 16, wherein

R^3 is halogen or C_{1-10}- alkyl, optionally substituted by halogen, up to perhaloalkyl;

R^4 is H, halogen or NO_2;

R^5 is H, halogen or C_{1-10}- alkyl;

R^6 is H , C_{1-10}- alkoxy, thiophene, pyrole or methylsubstituted pyrole

$R^{3'}$ is H, halogen, C_{4-10}-alkyl, or CF_3 and

$R^{6'}$ is H, halogen, CH_3 , CF_3 or OCH_3.

18. (Amended) A method according to claim 16, wherein M is $-CH_2-$,–S-, $-N(CH_3)-$ or –NHC(O)- and L^1 is phenyl or pyridyl.

19. (Amended) A method according to claim 16, wherein M is –O- and L^1 is phenyl, pyridone, pyrimidine, pyridyl or benzothiazole.